drugset
drugset / Trial / NCT00049101

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00049101 ↗

Phase 1/2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib with oxaliplatin, leucovorin, and fluorouracil in treating patients who have metastatic colorectal cancer.

Timeline

Start
2002-08
Primary completion
—
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral
Background Leucovorin Small molecule — Intravenous
Background Oxaliplatin Small molecule — Intravenous
Background fluorouracil Small molecule — Intravenous

Indications

colorectal cancer